988 OUTCOMES OF HEPATITIS C SCREENING PROGRAMS TARGETED AT RISK GROUPS HIDDEN IN THE GENERAL POPULATION: A SYSTEMATIC REVIEW

Background. Infection withChlamydia trachomatis(CT) can lead to reproductive sequelae. Information on the general population of childbearing age women in India is sparse. We reviewed the literature on CT prevalence within the general population of reproductive aged women in order to improve the efforts of public health screening programs and interventions.Objective. To conduct a literature review to determine the prevalence ofChlamydia trachomatisamong childbearing age women in India.Search Strategy. Ovid Medline and PubMed databases were searched for articles from January 1, 2003, through December 31, 2014. Search terms included “Chlamydia trachomatis”, “CT”, “prevalence”, “India”, and “sexually transmitted infections”.Selection Criteria. Studies on prevalence data for CT among women of childbearing age (15–45) living in India were included.Data Collection and Analysis. Articles that met the inclusion criteria were extracted by two readers and discrepancies solved through discussion.Results. Reported prevalence of active CT infection among lower risk groups ranged from 0.1% to 1.1% and in higher risk group from 2.7% to 28.5%.Conclusion.CT prevalence among women in India is comparable to other countries. Screening programs to prevent adverse outcomes among Indian women of childbearing age and their offspring are warranted.

Download Full-text

Prevalence and burden of chronic kidney disease among the general population and high-risk groups in Africa: a systematic review

BMJ Open ◽

10.1136/bmjopen-2016-015069 ◽

2018 ◽

Vol 8 (1) ◽

pp. e015069 ◽

Cited By ~ 31

Author(s):

Samar Abd ElHafeez ◽

Davide Bolignano ◽

Graziella D’Arrigo ◽

Evangelia Dounousi ◽

Giovanni Tripepi ◽

...

Keyword(s):

Systematic Review ◽

Chronic Kidney Disease ◽

High Risk ◽

Kidney Disease ◽

General Population ◽

Risk Groups

Download Full-text

Prevalence of hepatitis C infection among the general population and high-risk groups in the EU/EEA: A systematic review update

10.21203/rs.2.9311/v2 ◽

2019 ◽

Author(s):

Ru HAN ◽

Junwen ZHOU ◽

Clément François N ◽

Mondher Toumi

Keyword(s):

Hepatitis C ◽

High Risk ◽

General Population ◽

Risk Groups ◽

Epidemiological Studies ◽

Resource Utilisation ◽

European Economic Area ◽

The European Union ◽

Hepatitis C Infection ◽

Healthcare Resource Utilisation

Abstract Background: Although significant improvement in efficacy measured by a sustained virological response, the high acquisition costs of direct-acting antivirals limit the access for patients and influence the costs of healthcare resource utilisation in hepatitis C. It is important to have the latest estimates of prevalence, especially in high-risk groups, for cost of illness, cost-effectiveness and budget impact studies. Methods: Original studies on the estimates of the prevalence among general and high-risk populations in the European Union/European Economic Area (EU/EEA) were retrieved from Medline and Embase for the period from 2015 to 2018. All included studies were evaluated for risk of selection bias and summarised together in a narrative form. Results from previous reviews and updated searches were compared per country among different populations, respectively. Results: Among the 3871 studies identified, 46 studies were included: 20 studies were used for the estimate of the general population; 3 for men who have sex with men (MSM); 6 for prisoners; and 17 for people who inject drugs (PWID). Compared with the results reported in previous systematic reviews, the updated estimates were lower than previously in most available countries. Anti-HCV general population prevalence estimates ranged from 0.54% to 1.50% by country. The highest prevalence of anti-HCV was found among PWID (range of 7.90% - 82.00%), followed by prisoners (7.00% - 41.00%), HIV-positive MSM (1.80% - 7.10%), HIV-negative MSM (0.20% - 1.80%), pregnant women (0.10% - 1.32%) and first-time blood donors (0.03% - 0.09%). Conclusions: Our study highlights the heterogeneity in anti-HCV prevalence across different population groups in EU/EEA. The prevalence also varies widely between European countries. There are many countries that are not represented in our results, highlighting the need for the development of robust epidemiological studies.

Download Full-text